Formulary considerations in selection of beta-blockers

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Health Economics

Background:

• Formulary addition of beta-adrenergic blockers presents challenges due to agent variability.
• Numerous pharmacodynamic and pharmacokinetic differences exist among available beta-blockers.

Purpose of the Study:

• To outline key characteristics for selecting cost-effective beta-blockers for formulary inclusion.
• To guide formulary decisions by highlighting critical differentiating factors of beta-blocker agents.

Main Methods:

• Review of clinical trial evidence comparing beta-blocker efficacy across various indications.
• Analysis of product formulations, including oral and intravenous availability, and sustained-release options.
• Evaluation of comparative drug costs and economic impact of patient compliance.

Main Results:

• Efficacy differences noted for post-myocardial infarction prophylaxis, anxiety, tremor, thyrotoxicosis, migraine prophylaxis, and esophageal varices bleeding prevention.
• Oral and intravenous formulations are crucial for cardioprotection and arrhythmia management.
• Beta-receptor selectivity, duration of action, and intrinsic sympathomimetic activity (ISA) significantly influence selection, unlike route of elimination or lipophilicity.

Conclusions:

• Formulary selection necessitates a comprehensive assessment of efficacy, formulation, and cost-effectiveness.
• Beta-1 selective agents may offer advantages for patients with COPD and diabetes.
• Longer duration of action and once or twice-daily dosing can improve compliance and economic efficiency.